Compare MAIN & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MAIN | VKTX |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.0B |
| IPO Year | 2014 | 2014 |
| Metric | MAIN | VKTX |
|---|---|---|
| Price | $56.27 | $28.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $61.57 | ★ $95.86 |
| AVG Volume (30 Days) | 394.2K | ★ 1.8M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 8.04% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.27 | N/A |
| Revenue Next Year | $5.14 | N/A |
| P/E Ratio | $61.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $48.95 | $24.52 |
| 52 Week High | $65.85 | $43.15 |
| Indicator | MAIN | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.02 | 30.44 |
| Support Level | $54.48 | $26.47 |
| Resistance Level | $56.39 | $35.36 |
| Average True Range (ATR) | 0.93 | 1.35 |
| MACD | -0.24 | -0.46 |
| Stochastic Oscillator | 16.53 | 6.26 |
Main Street Capital Corp is a principal investment firm focused on providing customized long-term debt and equity capital solutions to lower middle market ("LMM") companies and debt capital to private ("Private Loan") companies owned by or in the process of being acquired by a private equity fund. The group invests principally in secured debt investments, equity investments, warrants, and other securities of LMM companies, typically based in the U.S. The company operates as a single segment with a principal investment objective to maximize total return by generating current income from debt investments and current income and capital appreciation from equity and equity-related investments.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.